In the recent month, around the national university biomedical regional technology transfer and transformation center (Nanjing, Jiangsu) transformation platform construction, Nanjing Biomedical Valley staff are extraordinarily busy. Externally, they went to Peking University, Fudan University, China Pharmaceutical University and other more than ten universities to carry out in-depth communication, and formed part of the transformation of the cooperation intention; internally, they started to further sort out and upgrade the existing public service platform, and carefully laid out the construction of 18 functional sub-platforms according to the existing situation.
"Nanjing Biomedical Subcenter actually focuses on the transformation of university research results, which makes me both exhilarated and excited, and my team and I will do our best to prepare for a series of work." Dr. Kan Suli, General Manager of Jiangbei New District Biomedical Public Service Platform, said.
September 14, the Ministry of Education and Jiangsu Province signed a strategic cooperation agreement to build the first national university regional technology transfer center, Nanjing, Suzhou as the core carrying area, the first batch of biomedicine, information and communications, advanced materials, three major industrial directions, respectively, selected more than 20 domestic universities to participate in the construction. More than 20 domestic universities were selected to participate in the construction of the center. Among them, the Nanjing Biomedical Sub-center is located in Nanjing Biomedical Valley.
Why choose Nanjing for this "national center"? How will the center be built? What positive impact will it have in the future?
01Why Nanjing?
Three "first-mover" advantages
As the main force of basic research and the source of major scientific and technological breakthroughs, colleges and universities are "rich mines" of scientific and technological achievements, but in the process of promoting the transformation of achievements, there will always be a variety of "problems": the results of the disconnect between industrial demand, can not be turned; the maturity of the technology is not high, not good; Insufficient specialized capacity of the technology transfer talent team will not turn ...... It is in this context that the Ministry of Education has proposed to pilot the construction of regional technology transfer centers in some areas of national universities, docking national and regional industrial needs, and to form an effective model of scientific and technological innovation of universities to comprehensively support industrial innovation.
Facing the best universities in the country, the opportunity to transform the most advanced research results of the university into real productivity, for the region is naturally very attractive. Jiangsu was eventually selected as the "first in the country", taking into account the advantages of a solid industrial base, rich scientific and educational resources, excellent business environment, and a huge market.
In Kan Suli's view, Nanjing's development of the biomedical industryThree "first mover" advantages, is the most important factor for the sub-center to be able to settle down.
01
As the capital of Jiangsu Province, Nanjing has obvious location advantages.
Whether the center is docked to universities in the south or the north, or serving enterprises across the country, the traffic is very convenient, and the commuting time will not be very long, especially with the construction of the Nanjing North Railway Station, Nanjing Biomedical Valley's traffic convenience will be further improved. At the same time, the Valley in recent years to give full play to the new state-level zones and Pilot Free Trade Zone "dual-zone superposition" advantage, in-depth promotion of biomedicine industry chain open innovation, biopharmaceutical products manufacturing innovative industry cluster has become a national innovative industry clusters.
02
Nanjing has a large number of universities, hospitals and biomedical enterprises, with significant resource advantages, which can provide convenient conditions for "from research to production".
In Nanjing Biomedical Valley, the largest state-run public technology service platform has been built, and the platform serves the subject groups of universities across the countryOver 400In addition, the Pharmaceutical Valley Campus has already gatheredMore than 1100Biomedical enterprises, the enterprise gradient is complete, any transformation of scientific research results can find application scenarios in the corresponding enterprises.
03
Biomedicine, as a key emerging industry in Nanjing, has more prominent industrial advantages.
Kan Suli introduction, Nanjing biomedical industry ecology, especially the industry cultivation mode, more with the results of discovery, incubation until the industrialization of the "transformation of temperament", "Nanjing or, Jiangbei New Area or, a large number of listed companies, unicorn or gazelle enterprises, basically from the source of the beginning of cultivation, to the Pharmaceutical Valley, for example, the South Micro-medicine, Pharmacology and Biology, Shi and genetics and other star enterprises, are from the sapling into a towering tree. Pharmaceutical Valley, for example, the South Micro-medicine, Pharmacology and Biology, Shi and genetics and other star enterprises, are from the sapling into a big tree, so that Nanjing has the patience and experience to promote the transfer of scientific research results."
02How are centers built?
Creating a "whole chain" transformation system
As the first national university regional technology transfer center, the mission it carries is naturally unusual, and how the center is built is of great concern to the outside world.
At the end of September, the National University Regional Technology Transfer and Conversion Center (Jiangsu) Construction Promotion Conference was held in Nanjing, at which the Nanjing Biomedical Sub-center released its construction blueprint. The center will build a platform, promote transformation, gathering elements of three aspects of efforts to promote universities and enterprises "two-way run to", through the biomedical field of scientific and technological achievements in the "discovery, validation, transformation, application" of the whole chain, to create a university of scientific and technological achievements and innovation and entrepreneurship training "dual center". The "dual center" for the transformation of scientific and technological achievements and innovation and entrepreneurship training of universities.
In the field of biomedicine, the research and development of new drugs is a systematic project that requires countless trials and validations, all of which are supported by highly sophisticated equipment. Nanjing Biomedical Sub-center will set up 18 functional sub-platforms, including intelligent pharmacy platform, drug design and screening discovery platform, database and biosample bank platform, future technology research platform, and medical device and equipment platform.
"Previously, the biomedical public service platform of Jiangbei New Area has already possessed a large number of equipments with high technical service capacity, which have laid the foundation for the construction of the center." Kan Suli introduced that the center will also make full use of the resources in the district to play the role of enterprise technology platform.
For example, Pharmachem Biologicals is a leading enterprise in the field of model animals in China, with the world's largest number of mouse strains, and is a co-builder of the National Science and Technology Resources Sharing Service Platform. Zhao Jing, general manager of the company, introduced, "Our service targets include universities, research institutes and medical institutions, as well as biotechnology companies and new drug research and development companies. At present, the transformation through this platform of Pharmacom has covered almost all the important disease areas, supporting including hundreds of innovative chemical drugs, biomacromolecules, cell and gene therapies, and IND filings (new drug research applications) and transformation of live bacteria drugs every year."
In addition to hardware support, Nanjing Biomedical Sub-center will also strengthen its service guarantee in terms of funding and funds. It will make full use of financial tools such as diversified science and innovation guidance funds and science and innovation bonds to support the progress of clinical research in universities and affiliated hospitals, accelerate the proof of concept as well as the amplification of small and medium-sized trials, and set up an early start-up support fund for the process of university projects moving from the subject group to the industry. At the same time, it further introduces fault tolerance and risk response mechanisms, enriches the evaluation system of fund input, and ensures that the fund can invest in early, small, and hard science and technology.
It is worth mentioning that Nanjing Biomedical Subcenter will combine the policy advantages of early and pilot implementation in Nanjing Area of FTZ, introduce special policies, promote typical models, and create a special policy zone to escort the pilot tasks.
03 What are the prospects for development?
More "outputs" in the future
On the west side of Xinghuo Road in Jiangbei New Area, the modern industrial center of Jiangbei New Area, which consists of 11 white buildings, is covered with green trees and fragrant flowers and plants, and the creation of the central plaza and the central water feature makes the whole park more energetic, and the chic shapes of the buildings as well as the white façade make the sense of science and technology and the sense of modernity come to the forefront. Here, it will become the operation carrier of Nanjing Biomedical Sub-center, and it is foreseeable that hundreds of biomedical achievement transformation projects from major universities in China will be settled here soon.
The first co-built units of Nanjing Biomedical Sub-center are more than twenty famous universities and affiliated hospitals in China, and the researchers of the universities are full of expectations for the construction of the center.
"Previously, there were some bottlenecks in the transformation of achievements in universities, and the construction of the center is equivalent to opening a green channel for the transformation of scientific research achievements for universities across the country." Zhao Jin, professor and doctoral supervisor of Nanjing University, said that for university teachers, the two policies launched by Nanjing Biomedical Subcenter are very "friendly", one is to allow university teachers to choose to transform their own achievements, or to match a team with a teacher to transform, so that the teacher has a choice; the other is the financial support. The other is financial support, Nanjing Biomedical Sub-center has an investment committee, after the project has been evaluated and passed, teachers do not need to worry about financing.
Di Bin, vice president of the Institute of Science and Technology of China Pharmaceutical University, said that the construction of the Nanjing Biomedical Subcenter is very crucial for promoting the high-quality development of the biomedical industry in Nanjing and even the whole country. Previously, Nanjing lacked such an integrated transformation platform, with this platform, you can better connect the government, universities, enterprises, hospitals, and is conducive to focusing on the advantages of resources, to achieve synergistic operations, to attack some major projects, and to make greater contributions to the national R & D of innovative drugs. In Di Bin's view, Nanjing Biomedical Subcenter construction to the world-renowned Boston Biotechnology Center, the future "output" more results, to create a new global biomedical innovation and R & D high ground.
In addition to university teachers, enterprises will also benefit from this. According to the operation mechanism of Nanjing Biomedical Sub-center, it is necessary to strengthen the deep integration of industry, academia and research led by enterprises, to establish a regular docking mechanism with leading scientific and technological enterprises, to sort out and release the technological needs of enterprises on a regular basis, and to select and answer questions jointly by enterprises and participating universities, and to carry out collaborative research between universities and enterprises in a way such as "enterprises make a list, universities make a list", and so on.
Imagine, in the near future, when a number of new drug creation of major technological bottlenecks in this breakthrough, high-end medical equipment research and development of core technologies to be overcome, the transfer of scientific research results of universities and colleges, will accelerate the development of the new quality of productivity to inject new momentum, the significance of self-evident.
